undamentalytics Newsletter
Sign in

Westlake Chemical Partners LP (WLKP) stock

Add to watchlist

Add holding +

NYSE: WLKP NYSE Commodity Chemicals Next results ~November 4, 2026

Westlake Chemical Partners LP is a US-listed company in the commodity chemicals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Westlake Chemical Partners LP is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Westlake Chemical Partners LP valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds27 adding, 17 cuttingOf 2 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Westlake Chemical Partners files

Where Westlake Chemical Partners LP stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.23bn, up 12.1% on a year earlier, slower than the 13.4% growth a quarter earlier. Free-cash-flow margin rose to 33.1% from 22.1% a year earlier. Operating margin narrowed to 28.8% from 30.8%. It passes 2 of our 3 financial-health checks.

Our model value for Westlake Chemical Partners is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Westlake Chemical Partners LP's trailing-twelve-month revenue grew 12.1% year on year, with a free-cash-flow margin of 33.1%.

Our discounted-cash-flow model values the business at ~$230 per share in the base case (~$170–$300 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 67.7% while net income grew 9.4%: a 58pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • High operating margin. 28.8% of revenue is left as operating profit.
  • Strong cash generation. 33.1% of revenue turned into free cash flow.

Things to watch

  • Share dilution. Diluted shares rose 8.7% in a year.
  • Gross margin slipping. Gross margin is down 2.2 points on a year ago.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$0.40 against an average estimate of $0.41: missed by 3.6%
Revenue
$297m, down 0.0% on a year earlier
Share reaction
0.0% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Next report
November 4, 2026; average EPS estimate $0.35

Westlake Chemical Partners' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.6%
  • 1 week+3.3%
  • 1 month+2.6%
  • This year+22.4%
  • 1 year+26.5%
  • 5 years+27.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.2B
Operating margin
28.8%
Net margin
4.7%

Growth

Revenue growth
+12.1%
Change in growth rate
−1.3 pts

Cash

Free cash flow (TTM)
$409M
FCF margin
33.1%

Earnings

Last results
August 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Westlake Chemical Partners LP valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Our value per share comes from a discounted-cash-flow model of Westlake Chemical Partners LP's free cash flow after stock-based pay ( $384M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation multiples over time Market data may be delayed

At fiscal year end 2015201620172018201920202021
Share price$9.67$10.07$12.32$12.76$15.12$15.00$18.18
Market value$262m$272m$350m$411m$522m$528m$640m
+ Net debt (− = net cash)−$170m−$89m−$27m−$20m−$20m−$17m−$17m
Enterprise value$92m$184m$323m$392m$502m$511m$623m
Multiples
Price / sales 0.3x0.3x0.3x0.3x0.5x0.5x0.5x
Price / earnings 6.6x6.7x7.2x8.3x8.6x8.0x7.8x
Price / free cash flow 1.2x—0.7x1.0x1.3x1.6x2.0x
EV / EBITDA 0.2x0.4x0.7x0.9x1.1x1.1x1.2x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

69 /100

Moderate moat

How hard Westlake Chemical Partners's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 5 / 20

    Net income has been a median 4.4% of total assets over 10 years.

  • Pricing power 11 / 20

    Gross margin has been a median 33.3%, moving by 3.5 percentage points (standard deviation) across 10 years.

  • Durability 20 / 20

    Operating margin has been a median 30.8%; its worst year was 26.3%.

  • Cash conversion 20 / 20

    Free cash flow was positive in 10 of 10 years, at a median 32.6% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, before the open. Analysts expect revenue of $336m and EPS of $0.35 (range $0.30 to $0.40) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1.54 +11% $1.4bn +16%
Next $1.85 +21% $1.4bn +5%

Next year's EPS estimate has moved −0.2% in 90 days, across 2 analysts.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.41 $0.40 −3.6%
Mar 2026 $0.40 $0.40 +0.6%
Dec 2025 $0.38 $0.41 +8.2%
Sept 2025 $0.45 $0.42 −6.6%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows Westlake Chemical Partners LP's revenue by +9.4% next year and +5.3% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+12.7%, weight 56%) and the company's own record (+5.3%, weight 44%) . How the weights are set.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611
  2. Sep 202611
  3. Aug 202611

Counts of recommendations published by analysts covering Westlake Chemical Partners LP, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.7%
of tradable shares
Days to cover
6.64
at average volume
Short interest, 1 month
+3%
to September 30, 2026
Held by institutions
29%
of shares
Held by insiders
44.8%
of shares

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +26.5%

$17.25 on October 31, 2025 to $21.82

ThenNowEffect
Revenue (last 12 months) $1.1bn $1.2bn +12.1%
Net margin 4.8% 4.7% −2.4%
P/E multiple 10.6x 12.2x +15.6%
Share count 32m 32m 0.0%

Biggest factor: p/e multiple.

Last 3 years +28.0%

$17.05 on November 3, 2023 to $21.82

ThenNowEffect
Revenue (last 12 months) $1.4bn $1.2bn −8.8%
Net margin 4.3% 4.7% +8.3%
P/E multiple 9.4x 12.2x +29.6%
Share count 32m 32m 0.0%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
WLKP+21%−6%+0%+16%−11%+22%
Industry peers (median)+30%−7%+7%−21%−37%+13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
WLKP50%58%50%50%50%73%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
WLKP−14%−29%−17%−7%−22%−9%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 60% from December 31, 2019 to March 18, 2020. Getting back needed a 151% gain, reached on February 1, 2021, 320 days after the low.

Price behaviour

52-week range
$16.77 – $22.83
From 52-week high
−4.4%
vs 50-day average
+2.1%
vs 200-day average
+1.7%
Volatility (1 year)
18%
Beta vs S&P 500
0.25

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±1.3%
After a week
7 up, 5 down
typical move ±1.9%
After a month
10 up, 2 down
typical move ±4.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 0.0% +1.6% +1.4% +6.2%
May 5, 2026 +3.4% +2.2% +3.8% +3.6%
February 24, 2026 +3.6% +1.6% +3.6% +5.5%
October 30, 2025 −0.5% −0.8% −1.4% +1.9%
August 5, 2025 +0.6% +0.3% +2.8% +2.4%
May 2, 2025 −2.7% +0.9% −3.1% −5.3%
February 24, 2025 −0.1% −1.0% −1.4% −4.7%
November 5, 2024 −0.6% +3.7% +2.7% +9.1%
August 6, 2024 0.0% +0.2% +1.0% +0.7%
May 1, 2024 +2.7% +0.6% +0.6% +9.2%
February 20, 2024 −1.7% −0.5% −0.4% +0.5%
November 2, 2023 −0.1% +2.8% −1.1% +1.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Westlake Chemical Partners LP
$1.1B $1.1B $1.2B $1.2B $1.3B $1.3B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.3B Revenue (TTM), FY23 Q4: $1.2B Revenue (TTM), FY24 Q1: $1.2B Revenue (TTM), FY24 Q2: $1.2B Revenue (TTM), FY24 Q3: $1.1B Revenue (TTM), FY24 Q4: $1.1B Revenue (TTM), FY25 Q1: $1.1B Revenue (TTM), FY25 Q2: $1.1B Revenue (TTM), FY25 Q3: $1.1B Revenue (TTM), FY25 Q4: $1.2B Revenue (TTM), FY26 Q1: $1.2B Revenue (TTM), FY26 Q2: $1.2B $1.2B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.3B
FY23 Q4 $1.2B
FY24 Q1 $1.2B
FY24 Q2 $1.2B
FY24 Q3 $1.1B
FY24 Q4 $1.1B
FY25 Q1 $1.1B
FY25 Q2 $1.1B
FY25 Q3 $1.1B
FY25 Q4 $1.2B
FY26 Q1 $1.2B
FY26 Q2 $1.2B
Revenue growth, TTM YoY Westlake Chemical Partners LP
-30% -20% -10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -19.0% Revenue growth, TTM YoY, FY23 Q4: -25.3% Revenue growth, TTM YoY, FY24 Q1: -24.1% Revenue growth, TTM YoY, FY24 Q2: -12.3% Revenue growth, TTM YoY, FY24 Q3: -9.3% Revenue growth, TTM YoY, FY24 Q4: -4.6% Revenue growth, TTM YoY, FY25 Q1: -6.8% Revenue growth, TTM YoY, FY25 Q2: -7.2% Revenue growth, TTM YoY, FY25 Q3: -0.8% Revenue growth, TTM YoY, FY25 Q4: 2.7% Revenue growth, TTM YoY, FY26 Q1: 13.4% Revenue growth, TTM YoY, FY26 Q2: 12.1% 12.1%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -19.0%
FY23 Q4 -25.3%
FY24 Q1 -24.1%
FY24 Q2 -12.3%
FY24 Q3 -9.3%
FY24 Q4 -4.6%
FY25 Q1 -6.8%
FY25 Q2 -7.2%
FY25 Q3 -0.8%
FY25 Q4 2.7%
FY26 Q1 13.4%
FY26 Q2 12.1%
Operating margin (TTM) Westlake Chemical Partners LP
26% 28% 30% 32% 34% 36% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 28.6% Operating margin (TTM), FY23 Q4: 30.0% Operating margin (TTM), FY24 Q1: 30.4% Operating margin (TTM), FY24 Q2: 31.0% Operating margin (TTM), FY24 Q3: 34.2% Operating margin (TTM), FY24 Q4: 34.4% Operating margin (TTM), FY25 Q1: 31.4% Operating margin (TTM), FY25 Q2: 30.8% Operating margin (TTM), FY25 Q3: 28.4% Operating margin (TTM), FY25 Q4: 27.4% Operating margin (TTM), FY26 Q1: 29.1% Operating margin (TTM), FY26 Q2: 28.8% 28.8%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 28.6%
FY23 Q4 30.0%
FY24 Q1 30.4%
FY24 Q2 31.0%
FY24 Q3 34.2%
FY24 Q4 34.4%
FY25 Q1 31.4%
FY25 Q2 30.8%
FY25 Q3 28.4%
FY25 Q4 27.4%
FY26 Q1 29.1%
FY26 Q2 28.8%
FCF margin (TTM) Westlake Chemical Partners LP
10% 20% 30% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 33.7% FCF margin (TTM), FY23 Q4: 34.0% FCF margin (TTM), FY24 Q1: 31.5% FCF margin (TTM), FY24 Q2: 32.5% FCF margin (TTM), FY24 Q3: 36.0% FCF margin (TTM), FY24 Q4: 38.4% FCF margin (TTM), FY25 Q1: 34.1% FCF margin (TTM), FY25 Q2: 22.1% FCF margin (TTM), FY25 Q3: 18.4% FCF margin (TTM), FY25 Q4: 17.3% FCF margin (TTM), FY26 Q1: 22.4% FCF margin (TTM), FY26 Q2: 33.1% 33.1%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 33.7%
FY23 Q4 34.0%
FY24 Q1 31.5%
FY24 Q2 32.5%
FY24 Q3 36.0%
FY24 Q4 38.4%
FY25 Q1 34.1%
FY25 Q2 22.1%
FY25 Q3 18.4%
FY25 Q4 17.3%
FY26 Q1 22.4%
FY26 Q2 33.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Westlake Chemical Partners took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $1.2B
  2. Cost of revenue $819M · 70.2%
  3. Gross profit $348M · 29.8%
  4. Selling, general and admin $28.3M · 2.4%
  5. Operating income $320M · 27.4%
  6. Interest and other $270M · 23.2%
  7. Net income $48.7M · 4.2%

Shares of revenue. Source: Westlake Chemical Partners's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1,750 1,007 987 1,173 1,286 1,092 967 1,215 1,593 1,191 1,136 1,167 1,235
Gross profit 746 383 391 404 377 379 379 442 377 387 419 348 385
EBITDA 794 441 465 488 458 457 456 520 469 468 502 448 469
Operating income 717 359 366 374 350 350 353 411 348 358 390 320 356
Net income 14 40 41 49 49 61 66 83 64 54 62 49 58
Diluted EPS — $1.47 — — — — — — — — — — —
Growth (year on year)
Revenue — −42.4% −2.0% +18.9% +9.6% −15.1% −11.5% +25.7% +31.1% −25.3% −4.6% +2.7% +12.1%
EBITDA — −44.5% +5.5% +5.1% −6.1% −0.2% −0.3% +13.9% −9.8% −0.2% +7.4% −10.9% +7.3%
Operating income — −49.9% +2.0% +2.2% −6.6% +0.2% +0.8% +16.3% −15.3% +2.9% +9.2% −18.2% +4.7%
Net income — — +2.8% +18.9% +1.4% +23.6% +8.5% +24.8% −22.3% −15.4% +14.9% −21.9% +9.4%
Margins
Gross margin 42.6% 38.0% 39.7% 34.4% 29.3% 34.8% 39.2% 36.4% 23.7% 32.5% 36.9% 29.8% 31.2%
EBITDA margin 45.4% 43.7% 47.1% 41.6% 35.7% 41.9% 47.2% 42.8% 29.4% 39.3% 44.2% 38.4% 38.0%
Operating margin 41.0% 35.7% 37.1% 31.9% 27.2% 32.1% 36.5% 33.8% 21.8% 30.0% 34.4% 27.4% 28.8%
Net margin 0.8% 4.0% 4.1% 4.1% 3.8% 5.6% 6.8% 6.8% 4.0% 4.6% 5.5% 4.2% 4.7%
Free-cash-flow margin 22.9% 22.0% −1.2% 39.9% 30.8% 37.3% 34.8% 26.9% 25.7% 34.0% 38.4% 17.3% 33.1%
Cash flow
Cash from operations 604 453 288 537 436 451 373 408 464 452 485 280 466
Capital spending 203 231 300 69 40 44 37 81 54 47 49 79 57
Free cash flow 401 221 −12 468 396 407 336 327 410 405 436 202 409
Balance sheet
Cash 134 170 89 27 20 20 17 17 65 59 58 44 49
Total debt 0 0 0 0 0 0 0 0 400 0 0 0 0
Net debt (negative = net cash) −134 −170 −89 −27 −20 −20 −17 −17 335 −59 −58 −44 −49
Diluted shares 27m 27m 27m 28m 32m 34m 35m 35m — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $1.2bn
Short-term assets $158mLonger-term assets $1.1bn
What it owes, and who funded it · $448m
Short-term liabilities $46mLonger-term liabilities $402m
  • Short-term assets cover short-term liabilities $158m of assets due within a year against $46m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $158m short-term assets against $402m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of $356m against $22m of interest.

From Westlake Chemical Partners LP's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Sales & admin spending
2.4%
of revenue

Competitors: side by side with peers

Closest by revenue in commodity chemicals
Last 12 months unless stated WLKP RYAM ASIX OEC KOP KRO Median
Revenue, last 12 months $1.2bn $1.5bn $1.6bn $1.8bn $1.9bn $1.9bn $2.1bn
Revenue growth, last 12 months 12.1% −3.3% 3.0% −1.0% −5.0% 2.7% 1.0%
Revenue growth, 3-year average −3.0% −6.9% −3.0% −2.5% −3.5% 5.1% −2.5%
Revenue growth, latest quarter −0.0% 10.6% 2.7% 7.4% 3.0% 12.9% 7.4%
Gross margin 31.2% 5.9% 5.6% 18.4% 22.4% 11.8% 13.3%
Operating margin 28.8% −3.5% — −0.2% −2.2% −1.7% −1.7%
Operating margin, 3-year average 30.2% −2.3% — 4.2% 4.2% 1.9% 4.2%
Net margin 4.7% −9.5% −1.1% −5.3% −4.6% −5.6% −4.0%
Cash from operations / revenue 37.7% 3.5% 5.5% 9.7% 10.1% 4.4% 6.3%
Free-cash-flow margin 33.1% −5.8% −1.7% 1.4% 7.3% 1.2% 3.1%
Free-cash-flow margin, 3-year average 29.2% −2.1% −0.8% −0.7% 4.6% 0.6% 0.7%
Stock pay / revenue — 0.3% 0.4% 0.6% 0.6% — 0.4%
Change in share count 8.7% 2.6% −0.1% −1.4% −2.5% 0.0% 0.2%

Median of all 14 companies we cover in commodity chemicals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$228M
Institutions reporting
56
Shares held vs prior quarter
▼ 0.2%
Positions opened / closed
5 / 4

Top buyers and sellers, Q2 2026: 27 institutions bought and 17 sold ; the biggest buyer was Mirae Asset Global Etfs Holdings Ltd (+28K shares) and the biggest seller Bank Of America Corp (−54K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Invesco Ltd. $111M 5.0M 48.6% 0.0%
Energy Income Partners, LLC $35.4M 1.6M 15.5% ▲ 0.5%
Mirae Asset Global Etfs Holdings Ltd. $16M 720K 7.0% ▲ 4.1%
Clearbridge Investments, LLC $14.1M 634K 6.2% 0.0%
UBS Group AG $9.8M 442K 4.3% ▼ 3.4%
Goldman Sachs Group Inc $5.3M 238K 2.3% ▲ 8.5%
Citigroup Inc $4.9M 218K 2.1% ▼ 4.7%
Bank Of America Corp $3.9M 174K 1.7% ▼ 23.6%
Morgan Stanley $3.8M 170K 1.7% ▼ 5.7%
Pathway Financial Advisers, LLC $2.4M 108K 1.1% ▲ 1.2%
Jpmorgan Chase & Co $2.1M 95K 0.9% ▲ 1.3%
Gilman Hill Asset Management, LLC $2M 88K 0.9% ▲ 1.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Westlake Chemical Partners LP's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 29, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 5, 2026
  • February 24, 2026
  • October 30, 2025
  • August 5, 2025
  • May 2, 2025

Recent SEC filings

Data status

When each part of this page on Westlake Chemical Partners LP was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Westlake Chemical Partners LP in brief

What does Westlake Chemical Partners LP do?
Westlake Chemical Partners LP is a US-listed company in the commodity chemicals industry. Its financial year ends in December.
What is Westlake Chemical Partners LP's stock ticker?
Westlake Chemical Partners LP trades under the ticker WLKP on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Westlake Chemical Partners LP's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Westlake Chemical Partners LP reported revenue of $1.2B, 12.1% higher than a year earlier, according to its SEC filings.
What is Westlake Chemical Partners LP's free cash flow?
Westlake Chemical Partners LP's free-cash-flow margin is 33.1% of revenue over the trailing twelve months.
Who are Westlake Chemical Partners LP's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Invesco Ltd., Energy Income Partners, LLC and Mirae Asset Global Etfs Holdings Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Westlake Chemical Partners LP's market cap?
On December 31, 2021, Westlake Chemical Partners LP's market capitalisation was about $640M, with a price-to-earnings ratio of 7.8 and net debt of -$17.1M. Market figures come from third-party market data and may be delayed.
Who are Westlake Chemical Partners LP's competitors?
In our Commodity Chemicals peer group, the companies closest to Westlake Chemical Partners LP are Rayonier Advanced Materials Inc., Advansix Inc., Orion S.a., Koppers Holdings Inc. and Kronos Worldwide Inc. The side-by-side comparison below sets their revenue, margins and growth against Westlake Chemical Partners LP's.
When is Westlake Chemical Partners LP's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Westlake Chemical Partners LP announces its own schedule.